TABLE 1.
Hydralazine reduces the increase in SBP without altering the development of cardiac hypertrophy in SHRa
| Group(s) | Age (wk) | n | Mean value ± SEM
|
|||
|---|---|---|---|---|---|---|
| BW (g) | HW (g) | HW/BW (mg/g) | SBP (mmHg) | |||
| WKY | 6 | 6 | 176.0 ± 4.1 | 1.51 ± 0.07 | 8.59 ± 0.37 | 105.0 ± 4.3 |
| SHR | 6 | 6 | 137.7 ± 4.0† | 1.16 ± 0.02† | 8.42 ± 0.24 | 133.3 ± 2.5† |
| WKY | 18 | 6 | 510.3 ± 9.3 | 2.16 ± 0.05 | 4.24 ± 0.11 | 114.2 ± 27 |
| SHR | 18 | 4 | 363.5 ± 8.7† | 1.72 ± 0.03† | 4.76 ± 0.16* | 191.2 ± 8.2† |
| SHR + Hyd | 18 | 6 | 386.7 ± 17.8† | 1.87 ± 0.05† | 4.85 ± 0.12* | 167.2 ± 3.9†‡ |
a
Body weight (BW), heart weight (HW), and SBP were determined in WKY, SHR, and SHR treated with hydralazine (Hyd) as described in Materials and Methods. * and †P < 0.05 and P < 0.01 versus WKY; ‡, P <0.05 versus SHR.